HBM Healthcare Investments AG Stock

Equities

HBMN

CH0012627250

Investment Management & Fund Operators

Market Closed - Swiss Exchange 11:30:11 2024-04-19 am EDT 5-day change 1st Jan Change
188 CHF +1.51% Intraday chart for HBM Healthcare Investments AG -0.53% +2.96%
Sales 2024 * -42.4M -46.54M Sales 2025 * 46.1M 50.6M Capitalization 1.3B 1.43B
Net income 2024 * -71M -77.94M Net income 2025 * 18M 19.76M EV / Sales 2024 * -29.9 x
Net cash position 2024 * 32M 35.13M Net cash position 2025 * 53M 58.18M EV / Sales 2025 * 27 x
P/E ratio 2024 *
-18.2 x
P/E ratio 2025 *
77.7 x
Employees 700
Yield 2024 *
3.99%
Yield 2025 *
2.99%
Free-Float 82.11%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.51%
1 week-0.95%
Current month-2.89%
1 month+0.64%
3 months+9.68%
6 months+21.13%
Current year+2.96%
More quotes
1 week
180.60
Extreme 180.6
190.40
1 month
180.60
Extreme 180.6
196.00
Current year
155.00
Extreme 155
196.00
1 year
135.20
Extreme 135.2
217.00
3 years
135.20
Extreme 135.2
367.00
5 years
135.20
Extreme 135.2
367.00
10 years
71.85
Extreme 71.85
367.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 01-06-30
Director of Finance/CFO 53 11-10-31
Corporate Secretary 60 -
Members of the board TitleAgeSince
Chairman 68 09-05-31
Director/Board Member 69 21-06-17
Director/Board Member 52 11-12-31
More insiders
Date Price Change Volume
24-04-19 188 +1.51% 4,378
24-04-18 185.2 -0.43% 3,109
24-04-17 186 +0.76% 2,851
24-04-16 184.6 -1.28% 4,818
24-04-15 187 -1.06% 6,057

Delayed Quote Swiss Exchange, April 19, 2024 at 11:30 am EDT

More quotes
HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
185.2 CHF
Average target price
236 CHF
Spread / Average Target
+27.43%
Consensus

Annual profits - Rate of surprise